台灣浩鼎生技股份有限公司 Approved
最後更新時間 2025/07/11 , 05:24 AM
最後更新時間 2025/07/11 , 05:24 AM
負責人
Liang,Geng-Yi
統一編號
13110677
成立日期
2002/04/29
資本額
NT$5,000,000,000
實收資本額
NT$2,631,593,740
股票代號
4174
電話
02-26558799
地址
6F, No. 508, Sec. 7, Zhongsiao E. Rd., Zhongnan Vil., Nangang Dist., Taipei City, 115, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Liang,Geng-Yi Chairman 1.24% SHENG CHENG INVESTMENT CO., LTD.
Ceng,Da-Meng Director 9.79% YI TAI INVESTMENT CO., LTD.
Ding,Wan-Fang Director 1.24% SHENG CHENG INVESTMENT CO., LTD.
Vacancy Director
Li,Shi-Ren Independent Director 0.00%
Chen,Ming-Jin Independent Director 0.00%
Qiu,Qin-Ting Independent Director 0.00%
營業項目
  • Wholesale of Pharmaceutical and Medical Goods(457112)
  • 公司歷程
  • Change Capital to 5,000,000,000
    2024/07/16
  • Change Person in Charge to Liang,Geng-Yi
    2024/01/08
  • Change Person in Charge to Yan,Yun
    2023/02/03
  • Change Capital to 3,000,000,000
    2015/01/16
  • Change Person in Charge to Zhang,Nian-Ci
    2013/02/26
  • Change Person in Charge to Ceng,Da-Meng
    2012/05/03
  • Change Capital to 1,500,000,000
    2011/03/14
  • 員工人數
    下載完整報告查看完整數據
    財務報表
    項目 2025 2024 2023
    Operating income 14,458 62,678 41,549
    Operating cost 30,641 138,952 115,046
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) -16,183 -76,274 -73,497
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net -16,183 -76,274 -73,497
    Operating expenses 495,222 2,295,254 2,016,294
    Other gain (loss), net - - -
    Operating profit (loss) -511,405 -2,371,528 -2,089,791
    Non-operating income and expenses -36,484 -124,680 814,237
    Net profit (loss) before tax -547,889 -2,496,208 -1,275,554
    Income tax expense (benefits) 2,231 -3,562 -9,594
    Net profit (loss) of ongoing business for the current period -550,120 -2,492,646 -1,265,960
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period -550,120 -2,492,646 -1,265,960
    Other comprehensive profit (loss), net 1,528 2,803 1,348
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period -548,592 -2,489,843 -1,264,612
    Net profit (loss) attributable to owners of parent company -511,545 -2,310,026 -1,046,475
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests -38,575 -182,620 -219,485
    Comprehensive profit (loss) attributable to owners of parent company -510,017 -2,306,502 -1,045,096
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests -38,575 -183,341 -219,516
    Basic earnings per share (yuan) -1 -9 -4
    項目 2025 2024 2023
    Net cash inflow (outflow) from operating activities -662,742 -1,833,513 -1,652,980
    Net cash inflows (outflows) from investing activities -469,802 483,018 -2,795,361
    Net cash inflow (outflow) from financing activities 3,340 2,174,869 607,068
    Effect of Exchange Rate Changes on Cash and Cash Equivalents 1,435 8,399 -559
    Increase (decrease) in cash and cash equivalents in the current period -1,127,769 832,773 -3,841,832
    Beginning balance of cash and cash equivalents 1,732,050 899,277 4,741,109
    Ending balance of cash and cash equivalents 604,281 1,732,050 899,277
    項目 2025 2024 2023
    Current asset 2,768,183 3,439,783 3,167,316
    Non-current asset 2,125,901 2,213,909 2,443,798
    Total asset 4,894,084 5,653,692 5,611,114
    Current liability 219,066 412,370 165,842
    Non-current liability 398,660 421,015 491,830
    Total liability 617,726 833,385 657,672
    share capital 2,631,594 2,631,594 2,294,394
    Equity - secruity token - - -
    capital reserve 9,102,178 9,100,741 7,127,750
    retained earning -8,390,584 -7,879,039 -5,569,013
    Other equity -10,371 -12,089 -19,867
    Treasury stock -26,528 -26,533 -26,533
    Total equity attributable to owners of parent company 3,306,289 3,814,674 3,806,731
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests 970,069 1,005,633 1,146,711
    Total Equity 4,276,358 4,820,307 4,953,442
    Share capital awaiting retirement (unit: share) 0 0 0
    Issued shares of advance equity (unit: shares) 0 0 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 190,845 190,882 190,882
    Net asset value per share 12 14 16
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額 0
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額 0
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    2024 01-04 0~0.5M 0~0.5M
    2023 01-12 2~3M 0~0.5M
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    商標
  • EndoSymeOBI
  • GlycOBI
  • OBI PHARMA
  • GlycoDx
  • GloboVax
  • Globo Mune
  • 浩鼎
  • 專利
  • 預測人體免疫反應的方法
  • 預測人體免疫反應的方法
  • 用於治療和預防冠狀病毒感染的藥物組合物
  • 共軛生物分子、醫藥組成物及方法
  • 新穎皂素佐劑及其評估方法
  • 與Globo系列抗原結合之嵌合抗原受體及其用途
  • 抗體、醫藥組成物及其用途
  • 人類抗體、醫藥組合物、及其方法
  • 抗體、醫藥組合物及方法
  • 共軛生物分子、醫藥組成物及方法
  • 政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
  • Others
    2017, 2023
  • Confirmation of employment relationship, etc.
    2023, 2024
  • Compensation for damage, etc.
    2017, 2018
  • Request for damage compensation, etc.
    2020
  • 勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。